UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
December
16, 2010
Date of Report (Date of earliest event
reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
State
of New York
|
1-10113
|
11-0853640
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
of
Incorporation)
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d-2(b))
o Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
Item
5.02 Departure of Directors or
Principal Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)
On
December 16, 2010 we awarded cash bonuses to the executive officers listed
below, in the amounts provided:
Name
|
Title
|
Bonus Award
|
Andrew
D. Reddick
|
President
and Chief Executive Officer
|
$124,000
|
Robert
B. Jones
|
Senior
Vice President and Chief Operating Officer
|
$99,000
|
Peter
A. Clemens
|
Senior
Vice President and Chief Financial Officer
|
$88,000
|
Albert
W. Brzeczko
|
Vice
President, Technical Affairs
|
$47,000
|
Robert
A. Seiser
|
Vice
President, Controller and Treasurer
|
$28,000
|
James
F. Emigh
|
Vice
President, Marketing and Administration
|
$24,000
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
ACURA PHARMACEUTICALS, INC. | |||
Date: December
16, 2010
|
By:
|
/s/ Peter A. Clemens | |
Peter A. Clemens | |||
Senior Vice President & Chief Financial Officer | |||